What Fueled The Previous Growth In The Dravet Syndrome Market?
The dravet syndrome market has seen considerable growth due to a variety of factors.
• There has been robust growth in the Dravet Syndrome market size in the past few years. The market, which is expected to expand from $0.37 billion in 2024 to $0.40 billion in 2025, is poised to grow at a compound annual growth rate (CAGR) of 9.0%.
This growth during the historical period can be credited to factors such as the rising incidence of Dravet Syndrome, improved detection rates due to superior screening methods, a boost in funding for epilepsy research, enhanced incentives for orphan drugs by regulators, and increased acceptance of treatments based on cannabis.
What Is The Expected Growth In The Dravet Syndrome Market Size Evolve over the Forecast Period?
The dravet syndrome market is expected to maintain its strong growth trajectory in upcoming years.
• The market for Dravet syndrome is anticipated to experience robust growth in the forthcoming years. It is estimated to reach a market value of $0.56 billion in 2029 with a compound annual growth rate (CAGR) of 8.7%.
The projected growth during this period is likely to be due to increased insurance protections for rare diseases, escalated efforts in patient advocacy, improved cost-effectiveness of genetic testing, enhanced governmental backing for rare disease treatments, and the rise in specialty neurology clinics. Key trends during this predicted period encompass progress in gene therapy for managing seizures, heightened use of AI for prompt diagnosis, cultivation of precision medicine for customised treatments, advancements in epilepsy management drug delivery systems, and an enlarged reliance on telehealth for remote patient tracking.
What Main Forces Are Fueling Expansion In The Dravet Syndrome Market?
The surge in neurological disorders is anticipated to drive the expansion of the dravet syndrome market in the upcoming period. Neurological disorders encompass a broad set of conditions impacting the brain, nervous system, and spinal cord, causing complications in bodily functions such as cognition, movement, and sensation. Factors such as aging populations, shifting lifestyles, environmental triggers, enhanced diagnostic methods, and increasing instances of autoimmune diseases and neuroinfections contribute to the rise in neurological disorders. Dravet syndrome acts as a critical source of information for these disorders, promoting research into genetic anomalies, brain reactivity, and unique treatments that could aid a wide range of other neurological conditions. The European Brain Council, a non-profit organization based in Belgium, stated in April 2022 that there are over 600 neurological diseases and close to 300 psychiatric disorders affecting millions around the globe, including 65 million individuals with epilepsy. In Europe, about 10.5 million people are suffering from dementia, a number predicted to reach 18.7 million by 2050. Therefore, the increasing frequency of neurological disorders is fueling the dravet syndrome market's growth.
What Are The Primary Segments In The Global Dravet Syndrome Market?
The dravet syndrome market covered in this report is segmented –
1) By Treatment And Management: Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, Other Treatments And Management
2) By Diagnosis: Magnetic Resonance Imaging Testing, Electroencephalography Testing, Sodium Voltage-Gated Channel Alpha Subunit 1 Testing, Other Diagnosis
3) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
4) By End-user: Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End-users
Subsegments:
1) By Seizure Medications: Anticonvulsants, Benzodiazepines, Levetiracetam, Cannabidiol (CBD) based medications, Topiramate, Lamotrigine
2) By Ketogenic Diet: Standard Ketogenic Diet (SKD), Modified Atkins Diet (MAD), Low Glycemic Index Treatment (LGIT), MCT (Medium Chain Triglyceride) Diet
3) By Vagus Nerve Stimulation: Implantable Vagus Nerve Stimulator (VNS), Non-invasive Vagus Nerve Stimulation (NIVNS), Adjunct Therapy With VNS For Seizure Control
4) By Other Treatments and Management: Physical and Occupational Therapy, Speech Therapy, Epilepsy Surgery, Cognitive Behavioral Therapy (CBT), Genetic Counseling And Support
Pre-Book The Dravet Syndrome Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Dravet Syndrome Industry?
Prominent players in the dravet syndrome market are centering their efforts on advancements in precision medicine, including RNA-based therapies, to produce focused treatments that tackle the root genetic alterations linked to Dravet syndrome. These measures are intended to enhance effectiveness and minimize adverse reactions. RNA-based therapies utilize RNA molecules to alter gene expression or protein creation in a bid to remedy genetic disorders by addressing the root issues at a molecular level. For instance, Stoke Therapeutics Inc, a biotechnology firm based in the US, gained approval from the U.S. Food and Drug Administration (FDA) in December 2024 for zorevunersen as a treatment for dravet syndrome. This treatment aims to augment the expression of the SCN1A gene, which is frequently mutated in patients with dravet syndrome; hence it handles the inherent genetic insufficiency rather than just symptom management. The therapeutic approach harnesses RNA-based precision medicine to reinstate proper neuronal function, which could potentially reduce seizure rates and enhance cognitive results.
Who Are the Key Players In The Dravet Syndrome Market?
Major companies operating in the dravet syndrome market are:
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• UCB S.A.
• Eisai Co. Ltd.
• Jazz Pharmaceuticals plc
• H. Lundbeck A/S
• BioMarin Pharmaceutical Inc.
• PTC Therapeutics Inc.
• Supernus Pharmaceuticals Inc.
• Zogenix Inc.
• Biocodex S.A.
• Encoded Therapeutics Inc.
• Marinus Pharmaceuticals Inc.
• Arvelle Therapeutics GmbH
• Stoke Therapeutics Inc.
• Longboard Pharmaceuticals Inc.
• Xenon Pharmaceuticals Inc.
• Aeovian Pharmaceuticals Inc.
• GW Pharmaceuticals plc
• Ovid Therapeutics Inc.
What Is The Most Dominant Region In The Dravet Syndrome Market?
North America was the largest region in the dravet syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dravet syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
